Document is current
Any future updates will be listed below
-
Authors
DeCastro, Carlos
Sheinberg, Phillip
Han, Bing
Vallow, Susan https://orcid.org/0000-0002-9426-7632
Bermann, Georgina
Dhalke, Marion
Kumar, Rakesh
Dickie, Gavin
Galipeau, Nina
Lamoureux, Roger
Rupinski, Kaelyn
Lowe, Caitlyn
Nieves, Amber
de Fontbrune, Flore Sicre
de Latour, Regis Peffault
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04558918 at ClinicalTrials.govnct04820530 at ClinicalTrials.govDocuments that mention this clinical trial
Patient-Reported Meaningful Change in Symptoms and Impacts of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Three Phase III Clinical Trials of Iptacopan
https://doi.org/10.1007/s40271-025-00755-5
nct04747613 at ClinicalTrials.govDocuments that mention this clinical trial
Patient-Reported Meaningful Change in Symptoms and Impacts of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Three Phase III Clinical Trials of Iptacopan
https://doi.org/10.1007/s40271-025-00755-5
Documents that mention this clinical trial
Patient-Reported Meaningful Change in Symptoms and Impacts of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Three Phase III Clinical Trials of Iptacopan
https://doi.org/10.1007/s40271-025-00755-5
-
Funding
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
- License Information
-
More Information
Article History
Accepted: 1 July 2025
First Online: 22 July 2025
Declarations
:
: The research reported here, and the development of this manuscript, were supported by funding from Novartis.
: Gavin Dickie, Nina Galipeau, Roger Lamoureux, Kaelyn Rupinski, and Caitlyn Lowe are employees of Adelphi Values, which was compensated by Novartis AG for the conduct of the research reported here. Amber Nieves was an employee of Adelphi Values at the time the research reported here was conducted.
: Ethics approval was received for all patient interviews. Country and site-specific ethics approval was obtained for the conduct of patient experience interviews as part of the relevant clinical trial protocol approvals.
: All authors contributed to the study conception and design. Gavin Dickie, Nina Galipeau, Roger Lamoureux, Kaelyn Rupinski, Caitlyn Lowe, and Amber Nieves prepared material preparation and collected data. Gavin Dickie, Nina Galipeau, Roger Lamoureux, Kaelyn Rupinski, Caitlyn Lowe, Amber Nieves, Susan Vallow, Georgina Bermann, Marion Dhalke, and Rakesh Kumar analyzed the data. Roger Lamoureux wrote the first draft of the manuscript, and all authors commented on subsequent versions. All authors read and approved the final manuscript.
: The data that support the findings of this study are not publicly available due to reasons of sensitivity but are available from the corresponding author upon reasonable request.
